Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Treatment of Colon Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically verified locally advanced T3 or T4 colon cancer assessed by CT scan~* Analysis of KRAS, BRAF, PIK3CA~* Age ≥18 år~* Performance status ≤ 2~* Hematology~  * ANC ≥ 1.5x10\^9/l. Thrombocytes ≥ 100x10\^9/l.~* Biochemistry~  * Bilirubinaemia ≤ 3 x UNL. ALAT ≤ 5 x UNL~* Consent to translational research~* Fertile women must present a negative pregnancy test and use secure birth control during and 3 months after treatment.~* Written and orally informed consent.~Exclusion Criteria:~* Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrollment, active severe infections or other concurrent disease.~* Peripheral neuropathy NCI grade \>1~* Other malignant disease within 5 years prior to enrollment, except basal cell squamous carcinoma of the skin and cervical carcinoma-in-situ~* Other investigational treatment within 30 days prior to treatment start~* History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan.~* Bleeding tumors~* Hypersensitivity to one or more of the substances

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy only (Type: OTHER): Chemotherapy only, if mutations in KRAS, BRAF or PIK3CA gene
- Chemotherapy + biological treatment (Type: OTHER): Addition of biological treatment, if no mutations in KRAS, BRAF, and PIK3CA genes.

Based on this trial design, predict the completion outcome and termination type (if applicable).